Industry
Compounded GLP-1 Drugs Recalled Nationwide Over Safety Concerns
A nationwide recall has been issued for certain compounded GLP-1 medications, which are not FDA-approved and are not the same as brand-name versions like Ozempic or Wegovy. These compounded products, often made by compounding pharmacies to meet demand or offer lower-cost alternatives, are being pulled due to safety concerns. Patients and providers who have obtained these non-FDA-approved versions are affected and should check with suppliers for specifics on the affected lots. Details on the scope, triggering safety issue, and timeline were not specified in the source material.
Why it mattersState Medicaid agencies and MCOs covering compounded GLP-1s outside FDA-approved formulations face immediate exposure to patient safety and liability risk requiring prompt review of pharmacy benefit and utilization management policies.